May 2020

8 Articles


Tocilizumab for severe COVID-19: a promising intervention affecting inflammation and coagulation

16 May 2020
Author(s): Marcel Levi

The COVID-19 pandemic is causing significant morbidity and mortality worldwide. Although most patients experience predominantly a respiratory tract infection, a proportion of patients progresses to a... more

Internal Medicine Flashcard

Multiple cutaneous lesions and pulmonary cysts

19 May 2020
Author(s): Sudharsan Venkatesan, Henrik Falhammar

A 50-year-old woman presented with multiple cutaneous lesions that had been present for many years (Figure 1a and 1b) similar to other family members. Her past history was significant for... more


14 May 2020
Author(s): Manajyoti Yadav, Namrata Singhania, Saurabh K. Bansal

28-year-old woman with no significant past medical history presented with acute onset of sub-sternal chest pain at work. It was “pinching” type and got worse on deep breathing, coughing, leaning... more

Multiple facial prominences of benign origin

14 May 2020
Author(s): Rim Bourguiba, Claude Bachmeyer, Bruno Angelard

An 18-year-old girl sought medical advice for an asymptomatic prominence of the right malar region evolving for two years because of cosmetic concern. Her medical history was relevant for Salmonella... more

Internal Medicine Flashcards

Woman with sore throat, fever and abdominal pain

11 May 2020
Author(s): Pierrick Le Borgne, Claudia Brunhuber, Pascal Bilbault

A 32-year-old woman, presented to the Emergency Department (ED) with a 15-day fever, and a sore throat recently associated with a growing abdominal pain. At admission in the ED, the patient had... more

Original Article

Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study

22 May 2020
Author(s): Corrado Campochiaro, Emanuel Della-Torre, Giulio Cavalli, Giacomo De Luca, Marco Ripa, Nicola Boffini, Alessandro Tomelleri, Elena Baldissera, Patrizia Rovere-Querini, Annalisa Ruggeri, Giacomo Monti, Francesco De Cobelli, Alberto Zangrillo, Moreno Tresoldi, Antonella Castagna, Lorenzo Dagna, TOCI-RAF Study Group

Starting from December 2019, the World has faced a global pandemic of a novel coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [1]. As... more

Off-label use of tocilizumab for the treatment of SARS-CoV-2 pneumonia in Milan, Italy

21 May 2020
Author(s): Valentina Morena, Laura Milazzo, Letizia Oreni, Giovanna Bestetti, Tommaso Fossali, Cinzia Bassoli, Alessandro Torre, Maria Vittoria Cossu, Caterina Minari, Elisabetta Ballone, Andrea Perotti, Davide Mileto, Fosca Niero, Stefania Merli, Antonella Foschi, Stefania Vimercati, Giuliano Rizzardini, Salvatore Sollima, Lucia Bradanini, Laura Galimberti, Riccardo Colombo, Valeria Micheli, Cristina Negri, Anna Lisa Ridolfo, Luca Meroni, Massimo Galli, Spinello Antinori, Mario Corbellino

Figure 4 modified: A curves showing survival of participants with severe COVID-19 pneumonia treated with tocilizumab: B. Kaplan-meier survival curves in patients with severe COVID-19 stratified... more

Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia

14 May 2020
Author(s): Ruggero Capra, Nicola De Rossi, Flavia Mattioli, Giuseppe Romanelli, Cristina Scarpazza, Maria Pia Sormani, Stefania Cossi

The epidemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) originating in Wuhan has dramatically spread in Italy, with very high mortality rates (7960 deaths over 46065 positive... more


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.